Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants.
暂无分享,去创建一个
J. Raman | M. Kaag | G. Sjödahl | J. Warrick | Lauren Shuman | Guoli Chen | Suzanne B. Merrill | D. DeGraff | Vonn Walter
[1] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[2] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.
[3] K. Hoadley,et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. , 2017, European urology.
[4] T. Ørntoft,et al. Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer , 2017, Scientific Reports.
[5] M. Höglund,et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification , 2017, The Journal of pathology.
[6] J. Weinstein,et al. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. , 2016, European urology.
[7] B. Taylor,et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer , 2016, Nature Genetics.
[8] Katherine A. Hoadley,et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.
[9] K. Baggerly,et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.
[10] M. Ringnér,et al. A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.